Phase 4 N=359 Randomized Other

Clinical and Economic Implications of Genetic Testing for Warfarin Management

Blood Coagulation Disorders

Bottom Line

View on ClinicalTrials.gov: NCT00964353 ↗

Enrolled (actual)

359

Serious AEs

2.2%

Results posted

Nov 2019

Primary outcome: Primary: Inpatient Length of Stay — 6.8; 7.2 days

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: Warfarin (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Chicago
Primary completion: Aug 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Inpatient Length of Stay	6.8; 7.2	—
SECONDARY Supratherapeutic Dosing	2.2; 2.2	—

Summary

The purpose of this study is to explore how knowing genes that individuals inherit from their parents can make warfarin dosing more safe and effective. This study is being done to determine whether providing doctors with data on the genes their patients inherited and warfarin dosing recommendations based on those genes affects the costs and outcomes of care and after hospitalization for patients from different ethnic/racial backgrounds, and how physicians use this information in decision making.

Eligibility Criteria

Inclusion Criteria

warfarin-naive patients
ages 18 and older
are undergoing inpatient anticoagulation initiation with warfarin for diagnoses that necessitate anticoagulation

Exclusion Criteria

patients who are not warfarin-naive
17 years of age or younger

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00964353). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.